



TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/734,024
		Filing Date	December 11, 2003
		First Named Inventor	David B. Weiner, et al.
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	14	Attorney Docket Number	UPVG0005-101 (H1237)

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	David A. Sadewasser/Reg. No. 55,587
Signature	<i>David A. Sadewasser</i>
Date	March 12, 2004

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	David A. Sadewasser		
Signature	<i>David A. Sadewasser</i>	Date	March 12, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: David B. Weiner, et al.

Serial No.: 10/734,024

Group Art Unit: Not Yet Assigned

Filing Date: December 11, 2003

Examiner: Not Yet Assigned

**For: COMPOSITIONS AND METHODS FOR
THE ABROGATION OF CELLULAR PROLIFERATION
UTILIZING THE HUMAN IMMUNODEFICIENCY
VIRUS VPR PROTEIN**

DATE OF DEPOSIT: March 12, 2004
I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON
THE DATE INDICATED ABOVE AND IS ADDRESSED TO
THE COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VA 22313-1450

David A. Sadewasser
TYPED NAME: David A. Sadewasser
REGISTRATION NO: 55,587

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- ☒ **before** the mailing date of a first Office Action on the merits.
- ☐ **after** the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
 - ☐ the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);
- or**
- ☐ the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
- ☐ No fee is owed by the applicant(s).
- ☐ In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- ☐ **after** the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously with, the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), a Petition requesting consideration of the Information Disclosure Statement and the Petition Fee of \$130.00 set forth in 37 C.F.R. § 1.17(i)(1) (see "Statement," "Petition," and "Fees" below).
- ☒ Copies of references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are enclosed.

EXCEPT THAT:

- ☐ In view of the voluminous nature of reference @@@, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.

- ☒ Copies of references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 were previously cited by or submitted to the U.S. Patent and Trademark Office in parent application Serial No. 08/809,186 filed on June 24, 1997.
- ☒ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Statement under 37 C.F.R. § 1.97(e)

- ☐ The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

Fees

- ☒ No Fee is owed by the applicant(s).
- ☐ The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.
- ☐ The Petition Fee of \$130.00 under 37 C.F.R. § 1.17(i)(1) is enclosed herewith.

Method of Payment of Fees

- ☐ Attached is a check in the amount of \$_____. This form is submitted in duplicate.
- ☐ Charge Deposit Account No. 50-1275 in the amount of \$_____. This form is submitted in duplicate.
- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.

☒ No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,



David A. Sadewasser
Registration No. 55,587

Dated: March 12, 2004

COZEN O'CONNOR, P.C.
1900 Market Street, 5th Floor
Philadelphia, PA 19103-3508
(215) 665-2000 – Telephone
(215) 701-2013 - Facsimile



Form PTO-1449 Modified		Docket No. UPVG0005-101 (H1237)	Serial No. 10/734,0246
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant David B. Weiner et al.	
		Filing Date December 11, 2003	Group Not Yet Assigned
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Agarwal et al., "Glucocorticoid Antagonists", <i>FEBS Letters</i> , 1987, 217, 221-226	
	AB	Bakke, "Antagonistic effect of glucocorticoids on retinoic acid induced growth inhibition and morphological alterations of a human cell line", <i>Cancer Res.</i> , 1986, 46, 1275-1279	
	AC	Balotta et al., "Antisense phosphorothioate oligodeoxynucleotides targeted to the vpr gene inhibit human immunodeficiency virus type 1 replication in primary human macrophages", <i>J. Virol.</i> , 1993, 67, 4409-4414	
	AD	Baulieu, "The Steroid Hormone Antagonist RU486", <i>Endocrinology and Metabolism</i> , 1991, 20, 873	
	AE	Beato, "Gene regulation by steroid hormones", <i>Cell</i> , 1989, 56, 335-344	
	AF	Bodine and Litwack, "The glucocorticoid receptor and its endogenous regulators", <i>Receptor</i> , 1990, 1, 83-120	
	AG	Cohen et al., "Human immunodeficiency virus vpr, product is a virion-associated regulatory protein", <i>J. Virol.</i> , 1990, 64, 3097-3099	
	AH	Cohen et al., "Identification of HIV-1 vpr product and function", <i>J. AIDS</i> , 1990, 3, 11-18	
	AI	Dedera, et al., "Viral protein R of human immunodeficiency virus types 1 and 2 is dispensable for replication and cytopathogenicity in lymphoid cells", <i>J. Virol.</i> , 1989, 63, 3205-3208	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. UPVG0005-101 (H1237)	Serial No. 10/734,024
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant David B. Weiner et al.	
		Filing Date December 11, 2003	Group Not Yet Assigned
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AJ	Dietrich et al., "Antagonism of glucocorticoid induction of Epstein-Barr virus early antigens by different steroids in Daudi lymphoma cells", <i>J. Steroid Biochem.</i> , 1986, 24, 417-421	
	AK	Evans, "The Steroid and Thyroid Hormone Receptor Superfamily", <i>Science</i> , 1988, 240, 889-895	
	AL	Ghosh, "Glucocorticoid Receptor Binding Site in the Human Immunodeficiency Virus Long Terminal Repeat", <i>J. Virol.</i> , 1992, 66, 586-590	
	AM	Gorman et al., "The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA mediated transfection", <i>Proc. Natl. Acad. Sci. USA</i> , 1982, 79, 6777-6781	
	AN	Green and Chambon, "Nuclear receptors enhance our understanding of transcription regulation", <i>Trends. Genet.</i> , 1988, 4, 309-314	
	AO	Gronemeyer et al., "Mechanisms of Antihormone Action", <i>J. Steroid Biochem.</i> , 1992, 41, 217-221	
	AP	Haseltine, "Molecular biology of the human immunodeficiency virus type 1", <i>FASEB J.</i> , 1991, 5, 2349-2360	
	AQ	Hattori et al., "The human immunodeficiency virus type 2 vpr gene is essential for productive infection of human macrophages", <i>Proc. Natl. Acad. Sci. USA</i> , 1990, 87, 8080-8084	
	AR	Katsanakis et al., "The human immunodeficiency virus long terminal repeat contains sequences showing partial homology to glucocorticoid response elements", <i>Anticancer Res.</i> , 1991, 11, 381-383	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. UPVG0005-101 (H1237)	Serial No. 10/334,024
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant David B. Weiner et al.	
		Filing Date December 11, 2003	Group Not Yet Assigned
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AS	Koenig et al., "Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy", <i>Science</i> , 1986, 233, 1089-1093	
	AT	Kolesnitchenko and Snart, "Regulatory Elements in the Human Immunodeficiency Virus Type 1 Long Terminal Repeat LTR (HIV-1) Responsive to Steroid Hormone Stimulation", <i>AIDS Res. Hum. Retrov.</i> , 1992, 8, 1977	
	AU	Lang et al., "Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus", <i>J. Virol.</i> , 1993, 67, 902-912	
	AV	Laurence et al., "Effect of glucocorticoids on chronic human immunodeficiency virus (HIV) infection and HIV promoter-mediated transcription", <i>Blood</i> , 1990, 74, 291-297	
	AW	Miksicek et al., "Glucocorticoid responsiveness of the transcriptional enhancer of Moloney murine sarcoma virus", <i>Cell</i> , 1986, 46, 283-290	
	AX	Lavallee et al., "Requirement of the Pr55gag precursor for incorporation of the Vpr product into Human Immunodeficiency Virus type 1 Viral Particles", <i>J. Virol.</i> , 1994, 68, 1926-1934	
	AY	Lazar and Agarwal, "Evidence for an antagonist specific receptor that does not bind mineralocorticoid agonists", <i>Biochem. Biophys. Res. Commun.</i> , 1986, 134, 261-265	
	AZ	Levy et al., "Induction of cell differentiation by human immunodeficiency virus 1 vpr", <i>Cell</i> , 1993, 72, 541-550	
	BA	Levy et al., "Serum vpr regulates HIV-1 latency", <i>Proc. Nat. Acad. Sci. USA</i> , 1994, 91, 10873-10877	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. UPV60005-I01 (H1237)	Serial No. 10/734,024
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant David B. Weiner et al.	
		Filing Date December 11, 2003	Group Not Yet Assigned
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	BB	Lindenmeyer et al., "Glucocorticoid Receptor Monoclonal Antibodies Define the Biological Action of RU38486 in Intact 1316 Melanoma Cells", <i>Cancer Res.</i> , 1990, 50, 7985-7991	
	BC	Lu et al., "Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions", <i>J. Virol.</i> , 1993, 67, 6542-6550	
	BD	Madan and DeFranco, "Bidirectional transport of glucocorticoid receptors across the nuclear envelope", <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90, 3588-3592	
	BE	Merrifield, "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide" <i>J. Am. Chem. Soc.</i> , 1963, 15, 2149-2154	
	BF	Newmeyer and Forbes, "Nuclear import can be separated into distinct steps in vitro: nuclear pore binding and translocation", <i>Cell</i> , 1988, 52, 641-653	
	BG	Ogawa et al., "Mutational analysis of the human immunodeficiency virus vpr open reading frame", <i>J. Virol.</i> , 1989, 63, 4110-4114	
	BH	Parker, "Introduction; Growth Regulation by Nuclear Hormone Receptors", <i>Cancer Surv.</i> , 1992, 14, 1-4	
	BI	Paxton et al., "Incorporation of vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis", <i>J. Virol.</i> , 1993, 67, 7229-7237	
	BJ	Perrot-Appianat et al., "Immunolocalization of steroid hormone receptors in Normal and Tumour Cells: Mechanisms of their cellular traffic", <i>Cancer Surv.</i> , 1992, 14, 5-30	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. UPVG0008-01 (H1237)	Serial No. 10/809,0286
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant David B. Weiner et al.	
		Filing Date December 11, 2003	Group Not Yet Assigned
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	BK	Picard and Yamamoto, "Two signals mediate hormone-dependent nuclear localization, of the glucocorticoid receptor", <i>EMBO</i> , 1987, 6(11), 3333-3340	
	BL	Phizicky et al., "Protein-Protein Interactions: Methods for Detection and Analysis", <i>Microbiol. Rev.</i> , 1995, 59, 94-123	
	BM	Richardson, et al., "Nuclear protein migration involves two steps: rapid binding at the nuclear envelope followed by slower translocation through nuclear pores", <i>Cell</i> , 1988, 52, 655-664	
	BN	Rogel M. et al., "The Human Immunodeficiency Virus Type 1 vpr Gene Prevents Cell Proliferation during Chronic Infection", <i>J. of Virology</i> , 1995, 69(2), 882-888	
	BO	Shibata et al., "Mutational analysis of the human immunodeficiency virus type 2 (HIV-2) genome in relation to HIV-1 and simian immunodeficiency virus SIV _{MAC} ", <i>J. Virol.</i> , 1990, 64, 742-747	
	BP	Weiner, "A point mutation in the neu oncogene mimics ligand induction", <i>Nature</i> , 1989, 339, 230-231	
	BQ	Westervelt et al., "Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants", <i>J. Virol.</i> , 1992, 66, 3925-3931	
	BR	Yuan et al., "Human immunodeficiency virus vpr gene encodes a virion-associated protein", <i>AIDS Res. Hum. Retrovir.</i> , 1990, 6, 1265-1271	
	BS	Zwerner et al., "Cell Culture", <i>Methods in Enzymology</i> , Jakoby and Pastan (eds.), Academic Press, San Diego, CA, 1979, Ch. 18, Vol. 58, 221-229	
	BT	Zhao et al., "Biochemical Mechanism of HIV-1 Vpr Function", <i>J. Biol. Chem.</i> , 1994, 269, 15577-15582	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. UPVG0005-101	Serial No. 10/734,024
		Applicant David B. Weiner et al.	
		Filing Date December 11, 2003	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	BU	Chantal-Petit et al., "Human Immunodeficiency Virus Infection Down-Regulates HLA Class II Expression and Induces Differentiation in Promonocytic U937 Cells", <i>J. Clin. Invest.</i> , 1987, 79, 1883-1889	
	BV	Fisher, "A molecular clone of HTLV-III with biological activity", <i>Nature</i> , 1985, 316, 262 -265	
	BW	Gendelman, "Trans-activation of the Human immunodeficiency virus long terminal repeat sequence by DNA viruses", <i>Proc. Natl. Acad. Sci. USA</i> , 1986, 83, 9759-9763	
	BX	Griffin et al., "Activation of HIV Gene Expression During Monocyte Differentiation by Induction of NF- κ B", <i>Nature</i> , 1988, 339, 70-73	
	BY	Heinzinger, N. et al., "The Vpr Protein of Human Immunodeficiency Virus Type 1 Influences Nuclear Localization of Viral Nucleic Acids in Nondividing Host Cells", <i>PNAS USA</i> , 1994, 91, 7311-7315	
	BZ	Holland et al., "RNA Virus Populations as Quasispecies", <i>Curr. Topics Microbiol. Immunol.</i> , 1992, 176, 1-20	
*	CA	Kent and Clark-Lewis, <i>Synthetic Peptides in Biology and Medicine</i> , Alitalo et al. (eds.), Science Publishers, Amsterdam, 1985, 295-358	
	CB	Korber, B. et al., "Signature Pattern Analysis: A Method for Assessing Viral Sequence Relatedness", <i>AIDS Res. Hum. Retroviruses</i> , 1992, 8(9), 1549-1560	
	CC	Levy, J., "Pathogenesis of Human Immunodeficiency Virus Infection", <i>Microbiol. Rev.</i> , 1993, 57(1), 183-289	
	CD	Myers, G. et al., "The Emergence of Simian/Human Immunodeficiency Viruses", <i>AIDS Res. Hum. Retrovir.</i> , 1992, 8(3), 373-386	
*	CE	Neurath et al. (eds.), <i>The Proteins</i> , 3d. Ed., Vol. II, Academic Press, New York, NY, 1976, 105-237	
EXAMINER		DATE CONSIDERED	

*A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous to send and easily obtainable by the Examiner.

Form PTO-1449 Modified		Docket No. UPVG0005-101	Serial No. 10/734,024
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Applicant David B. Weiner et al.	
		Filing Date December 11, 2003	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	CF	Phizicky et al., "Protein-Protein Interactions: Methods of Detection and Analysis", <i>Microbiol. Rev.</i> , 1995, 59(1), 94-123	
	CG	Ratner et al., "Complete nucleotide sequence of the AIDS virus, HTLV-III", <i>Science</i> , 1985, 313, 277-284	
	CH	Ratner et al., "Complete nucleotide Sequences of Functional Clones of the AIDS Virus", <i>AIDS Res. Hum. Retroviruses</i> , 1987, 3(1), 57-69	
	CI	Refaeli, Y. et al., "The Glucocorticoid Receptor Type II Complex is Target of the HIV-1 Vpr Gene Product", <i>PNAS USA</i> , 1995, 92, 3621-3625	
	CJ	Roulston et al., "Induction of Monocytic Differentiation and NF- κ B-like Activities by Human Immunodeficiency Virus 1 Infection of Myelomonoblastic Cells", <i>J. Exp. Med.</i> , 1992, 175, 751-763	
	CK	Salahuddin, S.Z. et al., "Human T Lymphotropic Virus Type III Infection of Human Alveolar Macrophages", <i>Blood</i> , 1986, 68(1), 281-284	
	CL	Starcich et al., "Characterization of Long Terminal Repeat Sequences of HTLV-III", <i>Science</i> , 1985, 227, 538-540	
	CM	Storrie et al., "Isolation of Subcellular Organelles", <i>Methods Enzymol.</i> , 1990, 182, 203-225	
	CN	Sutanto et al., "Corticosteroid receptor antagonists: a current perspective", <i>Pharm. World Sci.</i> , 1995, 17(2), 31-41	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. UPVG0005-100 (H1237)	Serial No. 10/734,024
		Applicant David B. Weiner et al.	
		Filing Date December 11, 2003	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	CO	Tindall et al., "Primary HIV infection: host responses and intervention strategies", AIDS, 1991, 5, 1-14	
	CP	Truss et al., "Steroid Hormone Receptors: Interaction with Deoxyribonucleic Acid and Transcription Factors", Endocrin. Rev., 1993, 14, 459-479	
	CQ	Wide, "Radioimmunoassay Method", Kirkham (ed.), E. & S. Livingstone, Edinburg, 1971, 405-412	
	CR	Valentin et al., "In Vitro Maturation of Mononuclear Phagocytes and Susceptibility to HIV-1 Infection", J. AIDS, 1991, 4, 751-759	
	CS	Wong-Staal, F. et al., "Human Immunodeficiency Virus: the Eighth Gene", AIDS Res. Hum. Retroviruses, 1987, 3(1), 33-39	
	CT	Yu et al., "Open Reading Frame vpr of Simian Immunodeficiency Virus Encodes a Virion-Associated Protein", J. Virol., 1990, 64(11), 5688-5693	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. UPVG00008-101		Serial No. 10/734,024	
				Applicant David B. Weiner et al.			
				Filing Date December 11, 2003		Group Not Yet Assigned	
U. S. PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
	CU	5,391,723	02/21/95	Priest	536	23.1	
	CV	5,346,696	09/13/94	Kim et al.	424	85.4	
**	CW	08/019,601	02/19/93	Weiner et al.			
**	CX	08/167,608	12/15/93	Weiner et al.			
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Translation YES NO		
	CY	WO 94/19456	09/01/94	PCT	X		
EXAMINER				DATE CONSIDERED			

**Pursuant to 37 C.F.R. 1.98(a)(2)(iii) no copy of a U.S. patent application need be included with the Information Disclosure Statement filed under 37 C.F.R. 1.97.